There are myriad studies which find very little difference in treatment effectiveness between Eylea and Lucentis, therefore it is likely that COAST & SHORE trials would produce similar results. That said Eylea has a an advantage in durability. If the phase 3 repeats previous results and demonstrates an approximate 30% improvement in visual acuity, then OPT is going to have a very popular drug in combination with either existing treatment.
Ann: Security Class Reinstatement to Quotation- OPTOB, page-126
-
- There are more pages in this discussion • 108 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.5¢ |
Change
0.005(0.82%) |
Mkt cap ! $757.1M | |||
| Open | High | Low | Value | Volume |
| 61.0¢ | 62.5¢ | 59.0¢ | $953.6K | 1.560M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22662 | 61.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 61.5¢ | 24454 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |